ArticleJournal of multidisciplinary healthcare2025
Clinical Research for Inherited Retinal Disease Related Pediatric Blindness: A Preliminary Descriptive Analysis Based on ClinicalTrials.gov.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Children with Disabilities and Chronic Diseases: Perspectives, Challenges, and Opportunities: A Guest Editorial for the Article Collection.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood blindness is a significant global health concern, consistently identified in existing research as stemming from rare genetic and congenital disorders. With the technological advances of the 21 Methods: A cross-sectional analysis was conducted using data from ClinicalTrials.gov. The initial search for data in ClinicalTrials.gov yielded a total of 110 studies under blindness-related conditions. Upon further cross-examination of these studies based on the inclusion criteria, only five interventional trials (published between 2012 and 2023) specifically targeting childhood blindness met the inclusion criteria and were therefore included. Key trial characteristics studied conditions, intervention types, outcome measures, study phases, and enrollment sizes were extracted and analyzed descriptively. Results: Across the five included trials, a majority of trials investigated rare genetic conditions, including Leber Congenital Amaurosis, Wolfram Syndrome, and Osteoporosis Pseudoglioma. On interventions, the most commonly used approaches for handling childhood blindness include gene therapy vectors like AAV RPE65, antisense oligonucleotides like QR-110, and repurposed pharmacological agents such as lithium and dantrolene sodium. All studies included children within their target populations, and most were early-phase (Phase 1/2) trials with small sample sizes (11-26 participants). Primary outcomes focused on safety, while secondary outcomes assessed visual function and biochemical changes. Conclusion: Although limited in number, current clinical trials represent a promising shift toward targeted therapies for childhood blindness. The dominance of early-phase studies highlights the need for expanded, multicenter, and later-phase trials. Future research should aim to improve trial accessibility, standardize outcome measures, and ensure ethical conduct in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.